Clinical Trial Search

Phase 3 N=1,729 Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Chronic Obstructive Pulmonary Disease (COPD)

Primary: Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1) — -0.030; 0.269; 0.213; 0.144 Liters — p=<0.0001

AstraZeneca Results Feb 2017 4.8% serious AE View details

Phase 3 N=77 Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

Primary: Rate of Acute Serious Bacterial Infections Per Year (ASBI) — 0.012 Estimated infections/ year — p=<0.0001

Baxalta now part of Shire Results Feb 2017 2.0% serious AE View details

Phase 3 N=112 Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Chronic Myocardial Ischemia · Refractory Angina Pectoris · Advanced Coronary Heart Disease

Primary: Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce Protocol — 108.7; 90.0 seconds

Lisata Therapeutics, Inc. Results Feb 2017 65.2% serious AE View details

Phase 3 N=882 Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Herpes Zoster

Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody — 206.0; 230.5; 395.6; 482.0 gpELISA…

Merck Sharp & Dohme LLC Results Feb 2017 1.2% serious AE View details

Phase 3 N=147 Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

Atrophic Acne Scar

Primary: ASRS Responder Rate at 6 Months — 32.4; 67.4 percentage of participants

Suneva Medical, Inc. Results Feb 2017 3.4% serious AE View details

Phase 3 N=211 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

Asthma

Primary: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 — 2.248; 2.246; 2.310; 2.261 Litre — p=0.040

AstraZeneca Results Feb 2017 1.9% serious AE View details

Phase 3 N=6 Collagenase Option for Reduction of Dupuytren's Contracture in Japan

Dupuytren's Contracture

Primary: The Percentage of Participants That Were Successfully Treated With a "Successful Reduction in Contracture to 5°or Less" — 86 % Participants

Asahi Kasei Therapeutics Corporation Results Feb 2017 13.7% serious AE View details

Phase 3 N=10 Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma

Asthma

Primary: The Rate of Number of Subjects Whose PC20 is Less Than 8 mg/mL — 7 percentage of the subjects

Santen Pharmaceutical Co., Ltd. Results Feb 2017 0.0% serious AE View details

Phase 3 N=70 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Childhood Atypical Teratoid/Rhabdoid Tumor

Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability

Children's Oncology Group Results Feb 2017 10.3% serious AE View details

Phase 3 N=222 A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

Primary: The Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 44.5; 7.1 percentage of participants — p=<0.001

Therapeutics, Inc. Results Feb 2017 0.4% serious AE View details

Phase 3 N=217 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Nail Psoriasis · Plaque Psoriasis

Primary: Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26 — 3.4; 46.6 percentage of participants…

AbbVie Results Feb 2017 4.7% serious AE View details

Phase 3 N=161 A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Post-Operative Pain

Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12). — 25.84; 13.14 units on a scale

Talphera, Inc Results Feb 2017 1.2% serious AE View details

Phase 3 N=217 Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Primary: DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo — 47; 10 percentage of participants — p=<0.0001

Intercept Pharmaceuticals Results Feb 2017 26.6% serious AE View details

Phase 3 N=119 Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram

Bipolar Disorder · Bipolar Depression

Primary: MADRS Rating Scale Change — 13.1; 15.2 units on a scale — p=0.17

Tufts Medical Center Results Feb 2017 0.8% serious AE View details

Phase 3 N=190 Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis

Otomycosis

Primary: Proportion of Subjects With a Complete Response to Treatment — 72; 66; 11; 11 participants

Salvat Results Feb 2017 0.0% serious AE View details